Platinum Investment Management Ltd. lifted its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) by 21.1% during the second quarter, Holdings Channel reports. The institutional investor owned 91,933 shares of the biopharmaceutical company’s stock after acquiring an additional 16,013 shares during the quarter. Platinum Investment Management Ltd.’s holdings in Sage Therapeutics were worth $4,323,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its position in Sage Therapeutics by 23.1% during the second quarter. JPMorgan Chase & Co. now owns 1,692,594 shares of the biopharmaceutical company’s stock worth $79,586,000 after purchasing an additional 317,276 shares in the last quarter. Northern Trust Corp boosted its position in Sage Therapeutics by 6.7% during the second quarter. Northern Trust Corp now owns 635,303 shares of the biopharmaceutical company’s stock worth $29,872,000 after purchasing an additional 39,871 shares in the last quarter. MetLife Investment Management LLC boosted its position in Sage Therapeutics by 2.1% during the second quarter. MetLife Investment Management LLC now owns 27,683 shares of the biopharmaceutical company’s stock worth $1,302,000 after purchasing an additional 558 shares in the last quarter. Edgestream Partners L.P. purchased a new position in Sage Therapeutics during the second quarter worth approximately $1,286,000. Finally, Commonwealth Equity Services LLC purchased a new position in Sage Therapeutics during the second quarter worth approximately $241,000. Hedge funds and other institutional investors own 89.68% of the company’s stock.
Sage Therapeutics Stock Performance
Shares of SAGE stock traded down $0.18 on Tuesday, hitting $19.54. 101,279 shares of the stock traded hands, compared to its average volume of 953,633. The firm’s 50-day moving average price is $19.61 and its two-hundred day moving average price is $33.26. The stock has a market capitalization of $1.17 billion, a PE ratio of -1.80 and a beta of 1.12. Sage Therapeutics, Inc. has a twelve month low of $16.51 and a twelve month high of $59.99.
Wall Street Analyst Weigh In
Sage Therapeutics Profile
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases.
- Five stocks we like better than Sage Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Wynn Resorts has an ace up its sleeve
- How to Invest in Grocery Stores
- Zoom Video Communications: A tech phoenix ready to rise
- How Can Investors Benefit From After-Hours Trading
- The only two airline stocks worth buying: One is a Goldman pick
Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.